ARDT · Ardent Health

The thesis

Ardent Health's cost-led hospital turnaround is running ahead of plan, and the evidence modestly favors the shares over the S&P 500 for the next three months. The 2027 outlook due with fourth-quarter results settles whether labor savings outrun Medicaid and exchange-coverage pressure.

The rating is Medium because the 4 November 2026 guidance raise is still drawing higher broker targets, while the share price already sits above the consensus target. Guggenheim raised its target to $21 from $14 with a Buy rating on 11 November 2026 (fiscal.ai), matching Stephens' $21 and above RBC Capital Markets' $18, both set on 6 November 2026 (Benzinga). The shares closed at $18.19 on 11 November 2026, up 65.1% over three months in adjusted daily closes.

The business case rests on costs. Third-quarter adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, with company adjustments) was $137.7 million against $45.3 million a year earlier, per the company's 8-K. Management raised the low end of 2026 guidance to $500 million from $485 million and kept the $535 million top.

The 2027 starting point is lower than the headline guidance. At the UBS Global Healthcare Conference on 10 November 2026, a finance executive put the 2027 starting point closer to $500 million of adjusted EBITDA, after removing an $11 million first-quarter unrealized gain and a few million dollars from the Kansas divestiture from the roughly $518 million midpoint (Investing.com, 11 November 2026). The $18.19 close sits above the $13.54 consensus target reported by Daily Political on 7 November 2026, so the price already reflects most of the cost program's success.

Bullish and bearish views on Ardent Health, Inc.

The bull case on Ardent Health, Inc. (ARDT), in brief: brokers keep raising targets. The bear case: the price is above the consensus.

Bull case

• Brokers keep raising targets. Guggenheim moved to $21 from $14 on 11 November 2026 (fiscal.ai), after Stephens moved to $21 from $13 and RBC to $18 from $13 on 6 November 2026 (Benzinga). Two of the three targets sit above the 11 November 2026 close of $18.19.
• Earnings beat on both lines. Third-quarter diluted earnings per share (EPS) were $0.31 against a $0.22 estimate, and revenue of $1.625 billion beat the $1.60 billion FactSet consensus (Benzinga and fiscal.ai, 4 November 2026). The company raised 2026 GAAP EPS guidance to $0.93–$1.18 from $0.78–$1.15 the same day.
• Labor costs are falling. Salaries and benefits were 39.9% of revenue, down from 42.9% a year earlier, and contract labor spending fell 45% (5 November 2026 earnings call).
• Physician fee growth is slowing. Professional fees grew 12.9% in the first quarter and 7.4% in the third (5 November 2026 call). Management expects 2027 growth above inflation but below the 2026 pace.
• The cost program runs for years. The IMPACT program delivered at least $70 million of 2026 savings, with $20 million to $25 million carrying into 2027, and the CFO said on 10 November 2026 it will run at least three more years. Management's long-term goal is a mid-teens EBITDA margin against 11.5% to 12% today (UBS conference, 10 November 2026).
• Payer rates are largely set. Ardent is 85% contracted for 2027 and 75% for 2028, and management expects 2027 commercial rate increases in the low double digits (UBS conference, 10 November 2026).
• The balance sheet gives room. Cash was $766 million, total debt about $1.1 billion and net leverage 0.8 times at 30 September 2026 (8-K). The company repurchased 1.0 million shares for $11 million in the third quarter.

Bear case

• The price is above the consensus. The $18.19 close on 11 November 2026 exceeds the $13.54 consensus target, and the consensus rating was Hold, with 7 buy, 6 hold and 2 sell ratings (Daily Political, 7 November 2026). Bank of America's target is $12, raised from $10.50 on 5 November 2026 (fiscal.ai).
• The 2027 starting point is about $500 million. Management's adjusted starting point of about $500 million on 10 November 2026 sits below the roughly $518 million 2026 midpoint, so 2027 growth is measured from a lower figure than the headline guidance.
• Medicaid adds a second $35 million hit. Management estimated Medicaid work requirements at roughly $35 million, similar to the $35 million 2026 exchange impact, and expects exchange pressure to continue in 2027 (UBS conference, 10 November 2026). Exchange admissions fell 7% in the third quarter (5 November 2026 call).
• Surgical volumes are weak. Adjusted admissions rose 2.9%, but admissions rose only 0.1% and surgeries fell 1.9%, with inpatient surgeries down 5.0% (8-K). The CFO tied weaker surgical demand to commercial and exchange patients with higher deductibles deferring care (10 November 2026).
• Revenue is not confirming the raise. The $6.4 billion to $6.7 billion revenue range was unchanged on 4 November 2026, and management pointed to the lower end on the 5 November 2026 call.
• The year-ago comparison flatters growth. Adjusted EBITDA was only $45.3 million in the third quarter of 2025 (8-K). Panabee's filing summary ties that quarter to a $43 million revenue adjustment for receivable collectability.
• Legal matters are open. Panabee's summary of company filings describes an SEC inquiry into 2025 revenue recognition, a securities class action and a $40 million liability settlement with a $34 million insurance recovery asset that carriers dispute.

Price setup

The shares closed at $12.99 on 4 November 2026, the session the third-quarter results were released, then at $15.90 on 5 November 2026 and $17.30 on 6 November 2026. They set a 52-week intraday high of $18.57 on 9 November 2026 and closed at $18.19 on 11 November 2026, 2.0% below that high. The 52-week closing low is $7.83 on 3 June 2026.

As of the 11 November 2026 close, the 50-day moving average was $11.87 and the 200-day moving average $10.26 in adjusted daily closes, so the price sits far above both. The shares held between $17.30 and $18.19 at the close over the four sessions to 11 November 2026, after the UBS conference remarks on 10 November 2026.

The 4 November 2026 close of $12.99 marks where the shares traded before the report; a close back under that area would erase the whole post-report gain. The only insider entries in SEC Form 4 filings since September are shares withheld for tax by three officers at $10.54 on 25 September 2026. The next quarterly report is not expected until about March 2027, which leaves broker revisions and the Kansas transfer as the nearer news.

Catalysts ahead

• ~31 December 2026 (est.): Expected closing of the Topeka, Kansas hospital transfer to Surgery Partners. Management expects an 11 times EBITDA price and a 0.40 percentage point margin benefit; closing shows whether portfolio pruning delivers as described.
• ~1 March 2027 (est.): Fourth-quarter 2026 report and 2027 guidance. The 2027 outlook against the roughly $500 million starting point management cited shows whether cost savings exceed Medicaid and exchange-coverage pressure.

What would change the view

A daily close below $13.00, the area of the $12.99 close on 4 November 2026 before the third-quarter report, which would erase the post-report gain. A 2026 adjusted EBITDA result under the $500 million low end, or a 2027 outlook below about $500 million, would also end the case.

The risks this note tracks, each with what would confirm it:

• Medicaid work requirements and exchange-plan attrition reduce 2027 paying volumes faster than cost savings offset them. Confirmed by: a 2027 adjusted EBITDA outlook below about $500 million, or exchange admissions falling by more than the 7% reported for Q3 2026.
• Professional fee growth accelerates again and absorbs labor savings. Confirmed by: quarterly professional fee growth above the 7.4% reported for Q3 2026.
• Weak surgical and commercial volumes keep revenue at the low end of guidance. Confirmed by: 2026 revenue under the $6.4 billion low end, or another year-over-year fall in total surgeries at the fourth-quarter report.
• The share price has run ahead of the consensus target and brokers turn cautious on valuation. Confirmed by: downgrades or target cuts citing valuation, pulling the consensus target further below the share price.
• Open legal matters described in filing summaries produce a charge or restatement. Confirmed by: an adverse SEC outcome, or a write-off of the $34 million disputed insurance recovery asset.

What it trades with

Ardent trades with US hospital operators that share its exposure to Medicaid eligibility rules and Affordable Care Act exchange enrollment; a policy change to Medicaid or exchange funding would hit the group and Ardent together. Surgery Partners is the buyer of Ardent's Topeka, Kansas hospital, which management called a one-off divestiture on 10 November 2026, and it shares Ardent's exposure to commercial surgical volumes. Ardent's rise since the 4 November 2026 report rests on its own cost results and guidance, so the shares can move apart from the group on company news.